Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAXIL vs Fluoxetine-Safety-Postpartum
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT) from the synaptic cleft, leading to increased serotonin levels.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder (off-label),Vasomotor symptoms of menopause (off-label)
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (off-label),Bipolar depression (off-label),Social anxiety disorder (off-label)
20 mg orally once daily, typically in the morning; may be increased in 10 mg/day increments at intervals of at least 1 week to a maximum of 50 mg/day.
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
Mean terminal half-life 21 hours (range 3–65 hours); steady-state achieved within 7–14 days; nonlinear kinetics with dose increase leading to disproportionate increases in half-life due to saturable hepatic metabolism (CYP2D6).
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Extensively metabolized primarily via cytochrome P450 (CYP) 2D6, with minor contributions from CYP3A4 and CYP1A2. The parent drug accounts for <1% of excretion. Metabolites include paroxetine catechol and paroxetine glucuronide conjugates.
Hepatic via CYP2D6, CYP2C9, CYP3A4; active metabolite norfluoxetine.
Renal: 64% (2% unchanged, 62% as metabolites); Fecal: 36% via bile; urinary excretion of unchanged paroxetine <2%.
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
93–95% bound to plasma proteins (primarily alpha-1-acid glycoprotein and albumin).
94% bound to albumin and alpha-1-acid glycoprotein
11 L/kg (range 3–28 L/kg); extensive tissue distribution with concentrations in CNS exceeding plasma.
12-43 L/kg; extensive tissue distribution including brain, breast milk.
Oral: 50% (range 30–60%; limited by first-pass metabolism); food does not significantly affect extent of absorption, but may slightly delay Tmax.
Oral: 95% (72% after first-pass); food may slightly decrease rate but not extent.
For GFR <30 m L/min: initial dose 10 mg/day; maximum 40 mg/day. Hemodialysis: no supplemental dose needed.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use cautiously with a maximum dose of 40 mg/day.
Child-Pugh Class A or B: initial dose 10 mg/day; maximum 40 mg/day. Child-Pugh Class C: not recommended.
Child-Pugh Class A: 20 mg every other day; Class B: 20 mg every third day; Class C: avoid use or use 10 mg every third day with careful monitoring.
Not approved for patients <18 years; off-label use for OCD in children 7–17 years: starting 10 mg/day, titrate by 10 mg/week to target 20–50 mg/day (max 60 mg/day).
Children (8-12 years): 10-20 mg orally once daily; adolescents (13-17 years): 20 mg orally once daily. Maximum 60 mg/day. Weight-based: 0.5-1.0 mg/kg/day, titrate to maximum 1.5 mg/kg/day.
Initial dose 10 mg/day; maximum 40 mg/day. Increase in 10 mg increments at intervals of at least 1 week.
Initial dose 10 mg orally once daily; titrate slowly to a maximum of 40 mg/day due to increased half-life and risk of hyponatremia and QT prolongation.
Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Paroxetine is not approved for use in pediatric patients.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality risk in children, adolescents, and young adults,Serotonin syndrome (potentially life-threatening) when co-administered with other serotonergic drugs,MAOI interaction (at least 14-day washout period),Discontinuation syndrome (dizziness, sensory disturbances, anxiety, etc.) upon abrupt withdrawal,Increased risk of bleeding (especially with NSAIDs, aspirin, or anticoagulants),Activation of mania/hypomania in patients with bipolar disorder,Seizure risk (use caution in patients with seizure disorders),Angle-closure glaucoma (pupillary dilation risk),Hyponatremia (elderly, volume-depleted patients),Bone fracture risk (epidemiological studies),Fetal harm (epidemiological data suggest increased risk of cardiovascular malformations, particularly ventricular outflow obstructions, with first-trimester exposure; consider risk/benefit)
Serotonin syndrome; risk of bleeding; activation of mania/hypomania; hyponatremia; discontinuation syndrome; QT prolongation (overdose).
Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Concurrent use of pimozide or thioridazine (QT prolongation and pharmacokinetic interaction),Hypersensitivity to paroxetine or any component of the formulation
Concurrent use with MAOIs (or within 14 days); concurrent use with thioridazine or pimozide; known hypersensitivity to fluoxetine.
No significant food interactions; may be taken with or without food. Grapefruit juice does not interact. Avoid excessive alcohol.
No specific food interactions; avoid grapefruit juice as it may increase fluoxetine levels. Take with or without food; if GI upset occurs, take with food.
First trimester: Risk of congenital cardiac defects (primarily ventricular and atrial septal defects) with relative risk ~1.5-1.7; persistent pulmonary hypertension of the newborn (PPHN) risk increased ~2-fold; overall absolute risk <.5% for major malformations. Second/third trimester: Risk of preterm delivery, low birth weight, neonatal serotonin discontinuation syndrome (irritability, feeding difficulties, respiratory distress, tremors).
First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/third trimester: Persistent pulmonary hypertension of the newborn (PPHN) risk ~1.5-2 times baseline; risk of preterm birth and low birth weight. Late third trimester: Risk of poor neonatal adaptation syndrome (PNAS) including jitteriness, respiratory distress, feeding difficulties, and irritability.
Paroxetine is excreted into breast milk with an estimated infant dose of ~1% of maternal weight-adjusted dose; M/P ratio is approximately 0.56. Cases of irritability, poor feeding, and drowsiness in breastfed infants have been reported; cautious use recommended, with monitoring for adverse effects.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk; M/P ratio ~0.3-1.0 for fluoxetine and ~0.5-2.0 for norfluoxetine. Relative infant dose approximately 2-12% of maternal weight-adjusted dose. Cases of colic, irritability, and poor feeding in breastfed infants have been reported. Generally considered compatible with breastfeeding; however, monitor infant for sedation, poor weight gain, and development.
Increased plasma volume and hepatic metabolism in pregnancy may reduce paroxetine levels; consider upward dose titration (20-40% increase) in second and third trimesters based on clinical response; monitor for worsening depression; taper gradually postpartum to avoid discontinuation syndrome.
Pregnancy increases fluoxetine clearance and decreases plasma concentrations, especially in the third trimester. Dose may need to be increased by 20-50% (e.g., from 20 mg to 30-40 mg daily) to maintain therapeutic effect. Consider therapeutic drug monitoring if available. Postpartum, dose should be reduced to pre-pregnancy levels within 48-72 hours due to reversal of pharmacokinetic changes.
Paroxetine has a short half-life and is associated with significant withdrawal syndrome upon abrupt discontinuation; taper slowly. It is the most anticholinergic SSRI, causing more constipation, dry mouth, and sedation. Use with caution in elderly due to hyponatremia risk. It is also a weak inhibitor of CYP2D6, potentially increasing levels of co-administered drugs like tamoxifen or metoprolol.
Fluoxetine has a long half-life (4-6 days, norfluoxetine 4-16 days) resulting in steady-state after 2-4 weeks; use lower starting doses (10 mg daily) in postpartum women to minimize side effects; monitor for neonatal adaptation syndrome if used in third trimester; consider dose adjustment in hepatic impairment; avoid in breastfeeding unless benefit outweighs risk due to presence in breast milk.
Take exactly as prescribed; do not stop suddenly or change dose without consulting doctor.,May cause drowsiness; avoid driving until you know how you react.,Avoid alcohol while taking this medication.,Notify doctor if you experience serotonin syndrome symptoms: agitation, hallucinations, fast heartbeat, fever, muscle stiffness, nausea, diarrhea.,Inform all healthcare providers you are taking paroxetine, especially before surgery or any new medication.,Do not take with MAOIs or within 14 days of stopping MAOIs.
Take fluoxetine exactly as prescribed, typically once daily in the morning.,It may take 4 weeks or longer to feel full benefit; do not stop abruptly.,Common side effects include nausea, headache, insomnia, and sexual dysfunction.,Contact your doctor if you experience rash, unusual bleeding, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not breastfeed without discussing risks with your healthcare provider.
No interactions on record
"Pazopanib, a tyrosine kinase inhibitor, inhibits CYP2D6 activity, leading to reduced metabolism of fluoxetine, a substrate of CYP2D6. This results in increased serum concentrations of fluoxetine and its active metabolite norfluoxetine, elevating the risk of serotonin-related adverse effects such as serotonin syndrome, nausea, and insomnia. The interaction is clinically significant and may require dose adjustment of fluoxetine."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"Concomitant use of tolcapone, a catechol-O-methyltransferase (COMT) inhibitor used in Parkinson's disease, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), may potentiate serotonergic effects leading to serotonin syndrome, characterized by autonomic instability, neuromuscular hyperactivity, and altered mental status. Additionally, both drugs undergo hepatic metabolism via CYP450 enzymes, and fluoxetine's inhibition of CYP2C9 and CYP3A4 may reduce tolcapone clearance, increasing the risk of hepatotoxicity and other adverse effects. The combination requires careful monitoring for signs of serotonin toxicity and liver injury."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAXIL vs Fluoxetine-Safety-Postpartum, answered by our medical review team.
PAXIL is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT) from the synaptic cleft, leading to increased serotonin levels.. Fluoxetine-Safety-Postpartum is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAXIL and Fluoxetine-Safety-Postpartum depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAXIL is: 20 mg orally once daily, typically in the morning; may be increased in 10 mg/day increments at intervals of at least 1 week to a maximum of 50 mg/day.. The standard adult dose of Fluoxetine-Safety-Postpartum is: 20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAXIL and Fluoxetine-Safety-Postpartum in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAXIL is classified as Category C. First trimester: Risk of congenital cardiac defects (primarily ventricular and atrial septal defects) with relative risk ~1.5-1.7; persistent pulmonary hypertension of the newborn . Fluoxetine-Safety-Postpartum is classified as Category A/B. First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.